Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
- Japan Pharmacist Group Opposes Off-Year Re-Pricing in FY2021
May 1, 2020
- PhRMA, EFPIA Issue Joint Statement on Air Transporting Critical Medicines amid COVID-19 Outbreak
April 30, 2020
- JMA Calls for Early Avigan Use in High-Risk Patients Hospitalized with COVID-19
April 30, 2020
- IFPW Postpones Tokyo General Meeting to October 2021
April 27, 2020
- SMA Patient Group Presses MHLW to Hasten Zolgensma Listing
April 17, 2020
- FPMAJ Ups Ante for Drug Supply Coordination amid COVID-19 Crisis
April 14, 2020
- EFPIA Japan Says No Drug Shortages for Now, but Warns of Fluid Situation
April 8, 2020
- JPMA to Vet Impact of Drug Pricing Reform, Make Proposals for R&D Tax Break System: FY2020 Project Plan
April 8, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- Keidanren Calls for Support in Drug, Vaccine Development: Emergency Proposal
March 31, 2020
- Japan Pharma Industry Presses for 100 Billion Yen Emergency Package over Coronavirus, Stable Supplies
March 31, 2020
- FPMAJ Launches Survey to Gauge COVID-19 Impact on Drug Supplies
March 27, 2020
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- JPMA Chief Fires Back at Health Policy Advisor’s “Plenty of Financial Strength” Comment
March 23, 2020
- JPMA Members Increasing Drug Stockpiles to Deal with COVID-19, Need Govt Support: Chief
March 23, 2020
- Japanese Drug Firms Providing APIs for NIID Screening for COVID-19: JPMA Survey
March 19, 2020
- Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…